PYLARIFY may have
helped avoid
undertreatment
PYLARIFY® prompted treatment change from prostatectomy
to systemic therapy, potentially avoiding undertreatment.
PYLARIFY may have helped avoid undertreatment
Actor portrayal for actual case study.
PYLARIFY® prompted treatment change from prostatectomy to systemic therapy, potentially avoiding undertreatment.
Actor portrayal for actual case study.
PYLARIFY may have
helped prevent
overtreatment
PYLARIFY may have helped prevent overtreatment,
which may be just as detrimental to patient health
as undertreatment.
PYLARIFY may have helped prevent overtreatment
Actor portrayal for actual case study.
PYLARIFY may have helped prevent overtreatment, which may be just as detrimental to patient health as undertreatment.
Actor portrayal for actual case study.
PYLARIFY helped avoid
toxic radiation therapy
NCCN guidelines-based recommendations would have
included pelvic radiation1.
PYLARIFY may have helped avoid radiation therapy
Actor portrayal for actual case study.
Historically, treatment would have included pelvic radiation.1
Actor portrayal for actual case study.
PYLARIFY identified
differences in extent of
disease
In patients with similar profiles, PYLARIFY identified
differences in extent of disease, guiding informed
treatment changes.*
PYLARIFY identified differences in extent of disease
Actor portrayals for actual case studies.
In patients with similar profiles, PYLARIFY identified differences in extent of disease, guiding treatment changes.*
Actor portrayals for actual case studies.
INDICATION
PYLARIFY (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:
- with suspected metastasis who are candidates for initial definitive therapy.
- with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
Hypersensitivity Reactions
Monitor patients for hypersensitivity reactions, particularly patients with a history of allergy to other drugs and foods. Reactions may be delayed. Always have trained staff and resuscitation equipment available.
Radiation Risks
INDICATION
PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:
- with suspected metastasis who are candidates for initial definitive therapy.
- with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
REFERENCE
- Achard V, Peyrottes A, Sargos P. How to manage T3b prostate cancer in the contemporary era: is radiotherapy the standard of care? Eur Urol Open Sci. 2023;53:60-62.
